Antitope Announces EpiScreen Collaboration with Abraxis BioScience, Inc.

September 29, 2010 -- Antitope Ltd., Cambridge UK (“Antitope”) today announced a they will be providing immunogenicity evaluation services for Abraxis BioScience LLC, Los Angeles, USA ("Abraxis") whereby Antitope will apply its proprietary EpiScreenTM technology to analyse the immunogenicity potential of selected therapeutic proteins developed by Abraxis.

“We are delighted to be working with Abraxis whose innovative discovery programmes and technologies are uncovering exciting new drug candidates for further investigation” said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope, adding, "The EpiScreenTM technology will enable us to assist Abraxis by providing a pre-clinical assessment of the immunogenicity of their therapeutics in order to select leads with low immunogenicity potential."

About Antitope Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanised antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.

For further information on Antitope visit;

http://www.antitope.co.uk or contact: Dr. Neil Butt Business Development Director, Antitope Ltd. Tel: +44 (0)1223 496190

About Abraxis

Abraxis BioScience (NASDAQ code AbII) is a fully integrated biotechnology company dedicated to delivering rogressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the world's first and only protein-based nanoparticle chemotherapeutic compound (ABRAXANE) which is based on its proprietary tumor targeting system known as the nab™ Technology platform. From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company's pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them.

For further information on Abraxis contact:

Corporate Communications Abraxis BioScience 11755 Wilshire Blvd. Suite 2000 Los Angeles, CA 90025 United States